Format

Send to

Choose Destination
Neurosci Biobehav Rev. 2015 Aug;55:478-97. doi: 10.1016/j.neubiorev.2015.06.005. Epub 2015 Jun 6.

When ageing meets the blues: Are current antidepressants effective in depressed aged patients?

Author information

1
Institut National de la Santé et de la recherche Médicale UMR-S 1178 Santé Mentale et Santé Publique, Université Paris-Sud, Fac Pharmacie, Université Paris Saclay, Châtenay-Malabry, France.
2
Department of Anatomy and Neuroscience, University College Cork, Ireland; Alimentary Pharmabiotic Centre, University College Cork, Ireland.
3
Department of Psychiatry, University College Cork, Ireland; Alimentary Pharmabiotic Centre, University College Cork, Ireland.
4
Lundbeck Research USA, Inc., 215 College Road, Paramus, NJ 07652, United States.
5
Institut National de la Santé et de la recherche Médicale UMR-S 1178 Santé Mentale et Santé Publique, Université Paris-Sud, Fac Pharmacie, Université Paris Saclay, Châtenay-Malabry, France. Electronic address: denis.david@u-psud.fr.

Abstract

"I had to wait 110 years to become famous. I wanted to enjoy it as long as possible.", Jeanne Louise Calment (1875-1997). This review summarizes current knowledge of the effects of antidepressant drugs in elderly patients (double-blind placebo (n=27) or active comparator-controlled clinical trials (n=21) indexed in Pubmed in depressed patients aged ≥60) and in aged mice (≥9 months) and middle-aged rats (≥14 months) on depression-related symptoms and cognitive performances. Finally, other potential therapeutic targets for treating depression-related disorders in elderly patients are also addressed (neurogenesis, GABAB receptor, 5-HT4 receptor, mTOR signaling). Overall, the very few published preclinical studies (n=12 in total) in middle-aged and aged rodents seem to suggest that selective serotonin reuptake inhibitors (SSRIs) may be less effective than tricyclic antidepressant drugs (TCAs) in ameliorating depression-like behavior and cognitive functions. On the other hand, results from clinical trials suggest that there is not a marked difference in efficacy and safety profiles of current marketed classes of antidepressant drugs.

KEYWORDS:

Aging; Cognition; Human; Major depressive disorders; Neurogenesis; Rodent

PMID:
26054791
DOI:
10.1016/j.neubiorev.2015.06.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center